We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




New AI System Performs as Well as Expert Pathologists in Identifying Prostate Cancer

By LabMedica International staff writers
Posted on 24 Feb 2020
Researchers at the Karolinska Institutet (Stockholm, Sweden) and Tampere University (Tampere, Finland) have developed a method based on artificial intelligence (AI) for histopathological diagnosis and grading of prostate cancer. More...
The AI-system has the potential to solve one of the bottlenecks in today's prostate cancer histopathology by providing more accurate diagnosis and better treatment decisions. A study conducted by the researchers showed that the AI-system was as good at identifying and grading prostate cancer as world-leading uro-pathologists.

Presently, prostate pathology involves some degree of subjectivity in the assessments of the biopsies and different pathologists can arrive at different conclusions even while studying similar samples. As a result, doctors are often required to choose treatment based on ambiguous information. The researchers see significant potential in the use of AI-technology to increase the reproducibility of the pathological assessments.

In order to train and test the AI system, the researchers digitized more than 8,000 biopsies taken from some 1,200 Swedish men in the ages of 50-69 to high-resolution images using digital pathology scanners. About 6,600 of the samples were used to train the AI system to spot the difference between biopsies with or without cancer. The remaining samples, and additional sets of samples collected from other labs, were used to test the AI system. Its results were also compared against the assessments of 23 world-leading uro-pathologists. The findings showed that the AI-system was almost near-perfect in determining whether a sample contained cancer or not, as well as in estimating the length of the cancer tumor in the biopsy. When it came to determining the severity of the prostate cancer, the so-called Gleason score, the AI system was on par with the international experts.

The initial findings are promising although more validation will be needed before the AI system can be rolled out broadly in clinical practice, according to the researchers. Currently, a multi-center study spanning nine European countries is underway with completion slated by the end of 2020. The study aims to train the AI-system to recognize cancer in biopsies taken from different laboratories, with different types of digital scanners and with very rare growth patterns. In addition, a randomized study starting this year will examine how the AI-model can be implemented in Sweden's health care system.

"Our results show that it is possible to train an AI-system to detect and grade prostate cancer on the same level as leading experts. This has the potential to significantly reduce the workload of uro-pathologists and allow them to focus on the most difficult cases," said Martin Eklund, associate professor at the Department of Medical Epidemiology and Biostatistics at Karolinska Institutet who led the study. "The idea is not that AI should replace the human involvement, but rather act as a safety net to ensure that pathologists don't miss some cancers, and assist in standardization of grading. It could also serve as an alternative in parts of the world where there is a complete lack of pathological expertise today."

Related Links:
Karolinska Institutet
Tampere University



Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
Serological Pipet Controller
PIPETBOY GENIUS
New
Integrated Biochemical & Immunological System
Biolumi CX8
New
Rapid Test Reader
DIA5000
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Molecular Diagnostics

view channel
Image: The RNA-seq based diagnostic test for pediatric leukemia ensures better outcomes for children with this common cancer (Photo courtesy of Qlucore)

RNA-Seq Based Diagnostic Test Enhances Diagnostic Accuracy of Pediatric Leukemia

A new unique test is set to reshape the way Acute Lymphoblastic Leukemia (BCP-ALL) samples can be analyzed. Qlucore (Lund, Sweden) has launched the first CE-marked RNA-seq based diagnostic test for pediatric... Read more

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: A simple blood test could replace surgical biopsies for early detecion of heart transplant rejection (Photo courtesy of Shutterstock)

Blood Test Detects Organ Rejection in Heart Transplant Patients

Following a heart transplant, patients are required to undergo surgical biopsies so that physicians can assess the possibility of organ rejection. Rejection happens when the recipient’s immune system identifies... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.